Alkem Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Alkem Laboratories Limited Pharmaceutical Export Portfolio Dataset — 30 Products, $247.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alkem Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 30 Products, $247.0M Trade | TransData Nexus

Alkem Laboratories Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $247.0M Total Trade · DGFT Verified

Alkem Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $247.0M across 30 products in 15 therapeutic categories. Based on 5,152 verified export shipments from Indian Customs (DGFT) records, Alkem Laboratories Limited is the #1 Indian exporter in 4 products including Cephalexin, Gabapentin, Colchicine. Top exports include Amlodipine ($37.3M), Cephalexin ($31.6M), Gabapentin ($27.3M).

Alkem Laboratories Limited — Export Portfolio & Destination Treemap

Alkem Laboratories Limited pharmaceutical export portfolio — 30 products across 15 therapeutic categories. Source: Indian Customs (DGFT).

Who is Alkem Laboratories Limited? — Company Overview & Market Position

Alkem Laboratories Limited, established in 1973, is a prominent Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the research, development, manufacture, and marketing of pharmaceutical formulations and nutraceuticals. Alkem's diverse product portfolio encompasses branded generics, generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and nutraceuticals, addressing a wide array of therapeutic areas such as anti-infective, gastroenterology, pain management, and more.

As of March 2025, Alkem reported a consolidated revenue of ₹12,964.5 million, reflecting a 2.3% increase from the previous fiscal year. The company employs approximately 18,642 individuals across its operations. Alkem's stock is publicly traded on the National Stock Exchange of India under the ticker symbol ALKEM.

What Does Alkem Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amlodipine$37.3M 2Cephalexin

Product Portfolio — Top 30 by Export Value

Alkem Laboratories Limited exports 30 pharmaceutical products across 15 therapeutic categories. Market leader (#1 exporter) in 4 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amlodipine	Cardiovascular	$37.3M	746	0.3%	4
2	Cephalexin	Antibiotics	$31.6M	631	8.8%	1
3	Gabapentin	CNS & Psychiatric	$27.3M	546	3.2%	1
4	Ezetimibe	Lipid & Metabolism	$19.4M	389	3.8%	2
5	Mycophenolate	Immunosuppressants	$18.3M	365	5.3%	3
6	Atorvastatin	Cardiovascular	$13.8M	277	1.3%	5
7	Metoprolol	Cardiovascular	$13.4M	269	1.7%	3
8	Metformin	Diabetes & Endocrine	$13.3M	289	2.8%	8
9	Cefuroxime	Advanced Antibiotics	$11.6M	231	8.9%	3
10	Tacrolimus	Immunosuppressants	$8.4M	168	4.2%	2
11	Ibuprofen	Analgesics & Antipyretics	$7.1M	142	1.2%	9
12	Ras	Ayurvedic & Herbal Products	$6.9M	138	2.2%	6
13	Everolimus	Immunosuppressants	$5.2M	112	12.5%	2
14	Linezolid	Advanced Antibiotics	$4.3M	85	11.3%	2
15	Nifedipine	Cardiovascular	$3.6M	85	12.0%	2
16	Sirolimus	Immunosuppressants	$2.9M	58	18.1%	2
17	Mesalamine	Gastrointestinal	$2.6M	52	0.2%	8
18	Valsartan	Cardiovascular	$2.5M	49	1.2%	10
19	Kit	Medical Devices & Diagnostics	$2.1M	67	0.5%	15
20	Lansoprazole	Gastrointestinal	$2.0M	40	0.7%	12
21	Gliclazide	Advanced Diabetes Medications	$2.0M	68	0.7%	14
22	Simvastatin	Cardiovascular	$1.9M	98	1.5%	13
23	Colchicine	Lipid & Metabolism	$1.7M	34	8.1%	1
24	Famotidine	Gastrointestinal	$1.6M	40	2.9%	8
25	Itraconazole	Antifungals	$1.5M	30	5.5%	5
26	Cefpodoxime	Advanced Antibiotics	$1.4M	29	1.8%	1
27	Capecitabine	Advanced Oncology	$1.2M	24	1.4%	2
28	Loratadine	Antihistamines & Allergy	$1.1M	38	0.7%	15
29	Minocycline	Advanced Antibiotics	$632.8K	37	2.8%	6
30	Azathioprine	Immunosuppressants	$413.9K	15	1.2%	7

Alkem Laboratories Limited exports 30 pharmaceutical products across 15 therapeutic categories with a total export value of $247.0M. The company is the #1 Indian exporter in 4 products: Cephalexin, Gabapentin, Colchicine, Cefpodoxime. The top category is Cardiovascular (29.4% of portfolio), followed by Immunosuppressants (14.2%), reflecting a diversified portfolio where the top 5 products account for only 54.2% of total value.

Alkem Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Alkem operates 19 state-of-the-art manufacturing facilities, with 17 located in India and 2 in the United States. These facilities are strategically designed to produce a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing plants are equipped with advanced technologies and adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at Alkem Laboratories Limited is headed by Executive Chairman Basudeo N. Singh and Chief Executive Officer Dr. Vikas Gupta. Dr. Gupta has been instrumental in steering the company's strategic direction and growth initiatives. Other key executives include Sandeep Derjit Singh, Managing Director and Executive Director; Mritunjay Kumar Singh, Executive Director; and Nitin Agrawal, Chief Financial Officer and President of Finance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Alkem Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Alkem Laboratories Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the United States, the company has filed 185 cumulative Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) and has received approvals for 156 ANDAs, including 13 tentative approvals. This robust pipeline underscores Alkem's commitment to expanding its footprint in the U.S. market.

In the European Union and the United Kingdom, Alkem's manufacturing facilities are accredited by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), ensuring compliance with stringent quality standards. The company's products are also registered in Australia and Japan, reflecting its dedication to meeting the regulatory requirements of these markets.

2Emerging Markets

Alkem Laboratories Limited has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are registered in over 40 countries, facilitating access to diverse markets and enhancing its global footprint. Additionally, Alkem's manufacturing facilities are accredited by the World Health Organization (WHO), enabling the company to supply products to countries requiring WHO prequalification.

Geographic Strategy

Alkem Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Alkem Laboratories Limited has a strong standing with the U.S. Food and Drug Administration (FDA). The company has filed 185 cumulative Abbreviated New Drug Applications (ANDAs) and has received approvals for 156 ANDAs, including 13 tentative approvals. This extensive portfolio demonstrates Alkem's commitment to providing high-quality generic pharmaceuticals in the U.S. market.

The company's manufacturing facilities are registered with the FDA, ensuring compliance with U.S. regulatory standards. Alkem's clinical research facility focuses on bioequivalence and bioavailability studies, further solidifying its position in the U.S. market.

2WHO & EU GMP

Alkem Laboratories Limited's manufacturing facilities are accredited by the World Health Organization (WHO), enabling the company to supply products to countries requiring WHO prequalification. Additionally, the company's facilities are certified with European Union Good Manufacturing Practice (EU GMP) standards, ensuring adherence to stringent quality requirements for the European market.

3CDSCO & Indian Regulatory

Alkem Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Alkem Laboratories Limited operates in a competitive landscape alongside other major Indian pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, and Cipla Ltd. In the fiscal year 2025, Alkem reported a consolidated revenue of $1.5 billion, reflecting a 2.3% increase from the previous year. This growth positions Alkem as a significant player in the global pharmaceutical market, competing effectively with its peers.

2Key Differentiators

Alkem Laboratories Limited distinguishes itself through its extensive product portfolio, which includes over 800 brands and more than 1,500 stock-keeping units (SKUs). The company's strong presence in the anti-infective segment, where it has maintained leadership for over a decade, further sets it apart. Additionally, Alkem's commitment to research and development, with an investment of ₹5,229 million in FY 2023-24, underscores its focus on innovation and quality.

3Strategic Position

Alkem Laboratories Limited's current strategic direction emphasizes the expansion of its generics portfolio, development of biosimilars, and strengthening of its contract development and manufacturing organization (CDMO) capabilities. The company's robust R&D infrastructure, comprising over 665 scientists across four facilities, supports these initiatives. Looking ahead, Alkem aims to enhance its global presence by leveraging its diversified product portfolio and manufacturing capabilities to meet the evolving needs of the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Alkem Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Alkem Laboratories Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a diverse product portfolio and a significant presence in both domestic and international markets. The company's manufacturing facilities are accredited by various international regulatory authorities, including the FDA, WHO, and EU GMP, indicating a high level of reliability and compliance. Alkem's commitment to quality is further evidenced by its leadership in the anti-infective segment and its substantial investment in R&D.

2Certifications to Verify

Importers should verify the following certifications when considering Alkem Laboratories Limited as a supplier:

FDA Registration: Confirm that Alkem's manufacturing facilities are registered with the U.S. Food and Drug Administration. This can be verified through the FDA's official website or by contacting the company directly.

WHO Prequalification: Ensure that Alkem's products are prequalified by the World Health Organization, which can be verified through the WHO's official website.

Frequently Asked Questions — Alkem Laboratories Limited

How many pharmaceutical products does Alkem Laboratories Limited export from India?

Alkem Laboratories Limited exports 30 pharmaceutical products across 15 therapeutic categories. The top exports are Amlodipine ($37.3M), Cephalexin ($31.6M), Gabapentin ($27.3M), Ezetimibe ($19.4M), Mycophenolate ($18.3M). Total export value is $247.0M.

What is Alkem Laboratories Limited's total pharmaceutical export value?

Alkem Laboratories Limited's total pharmaceutical export value is $247.0M, based on 5,152 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Alkem Laboratories Limited the #1 Indian exporter?

Alkem Laboratories Limited is the #1 Indian exporter in 4 products: Cephalexin (8.8% market share), Gabapentin (3.2% market share), Colchicine (8.1% market share), Cefpodoxime (1.8% market share).

What therapeutic categories does Alkem Laboratories Limited cover?

Alkem Laboratories Limited exports across 15 therapeutic categories. The largest are Cardiovascular (29.4%, 6 products), Immunosuppressants (14.2%, 5 products), Antibiotics (12.8%, 1 products).

Get Full Alkem Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.